CN111356692A - Ido抑制剂 - Google Patents

Ido抑制剂 Download PDF

Info

Publication number
CN111356692A
CN111356692A CN201880074353.2A CN201880074353A CN111356692A CN 111356692 A CN111356692 A CN 111356692A CN 201880074353 A CN201880074353 A CN 201880074353A CN 111356692 A CN111356692 A CN 111356692A
Authority
CN
China
Prior art keywords
compound
group
solution
pharmaceutically acceptable
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880074353.2A
Other languages
English (en)
Other versions
CN111356692B (zh
Inventor
周明
陆剑宇
胡国平
丁照中
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keystone
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Original Assignee
KEYSTONE
Medshine Discovery Inc
CStone Pharmaceuticals Shanghai Co Ltd
CStone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEYSTONE, Medshine Discovery Inc, CStone Pharmaceuticals Shanghai Co Ltd, CStone Pharmaceuticals Suzhou Co Ltd filed Critical KEYSTONE
Publication of CN111356692A publication Critical patent/CN111356692A/zh
Application granted granted Critical
Publication of CN111356692B publication Critical patent/CN111356692B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了新的一类作为IDO抑制剂的化合物，具体公开了式(I)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201880074353.2A 2017-12-19 2018-12-19 Ido抑制剂 Active CN111356692B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711375318 2017-12-19
CN2017113753188 2017-12-19
PCT/CN2018/122015 WO2019120212A1 (zh) 2017-12-19 2018-12-19 Ido抑制剂

Publications (2)

Publication Number Publication Date
CN111356692A true CN111356692A (zh) 2020-06-30
CN111356692B CN111356692B (zh) 2021-09-03

Family

ID=66993093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880074353.2A Active CN111356692B (zh) 2017-12-19 2018-12-19 Ido抑制剂

Country Status (3)

Country Link
CN (1) CN111356692B (zh)
TW (1) TW201927777A (zh)
WO (1) WO2019120212A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028846A1 (en) * 2000-10-03 2002-04-11 Dupont Pharmaceuticals Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
WO2003020699A2 (en) * 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2006062982A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
CN104619709A (zh) * 2012-07-13 2015-05-13 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
WO2017079519A1 (en) * 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
CN106715417A (zh) * 2014-04-04 2017-05-24 爱欧梅特制药公司 药物中使用的吲哚衍生物
CN106905256A (zh) * 2017-03-06 2017-06-30 中国药科大学 苯并五元杂环类ido1抑制剂、其制备方法及应用
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028846A1 (en) * 2000-10-03 2002-04-11 Dupont Pharmaceuticals Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
WO2003020699A2 (en) * 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2006062982A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
CN104619709A (zh) * 2012-07-13 2015-05-13 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
CN106715417A (zh) * 2014-04-04 2017-05-24 爱欧梅特制药公司 药物中使用的吲哚衍生物
WO2017079519A1 (en) * 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN106905256A (zh) * 2017-03-06 2017-06-30 中国药科大学 苯并五元杂环类ido1抑制剂、其制备方法及应用

Also Published As

Publication number Publication date
TW201927777A (zh) 2019-07-16
WO2019120212A1 (zh) 2019-06-27
CN111356692B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
CN112300195B (zh) 四并环类化合物及其制备方法和应用
CN110156786A (zh) 嘧啶并环化合物及其制备方法和应用
RU2747311C2 (ru) Ингибитор CDK4/6
CN113321654B (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
WO2021115457A1 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
CN112533916A (zh) 一种作用于crbn蛋白的三并环类化合物
CN114634510A (zh) 咪唑并吡啶衍生物及其用途
CN114907351A (zh) 三环类glp-1受体激动剂及其用途
CN115315427A (zh) Hpk1抑制剂及其制备方法和用途
CN110891569A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN114456147A (zh) 氧取代氨基碳酸酯噻吩类化合物
WO2023280280A1 (zh) 作为KRas G12D抑制剂的稠环化合物
JP2021513519A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2019079410A1 (en) ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
JP2023522725A (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
CN111356692B (zh) Ido抑制剂
CN112218871B (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
CN109206360B (zh) 咔唑酰胺类衍生物或其盐及其制备方法和用途
CN107522641B (zh) 联芳基脲类衍生物或其盐及其制备方法和用途
CN113166055A (zh) 雌激素受体拮抗剂
TWI823420B (zh) 用作cdk激酶抑制劑的化合物及其應用
WO2023083200A1 (zh) 吡唑并环化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201029

Address after: Unit E168 North building two building in Suzhou City, Jiangsu province Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY building A1

Applicant after: Cstone Pharmaceuticals (Suzhou) Co.,Ltd.

Applicant after: Cstone Pharmaceuticals (Shanghai) Co.,Ltd.

Applicant after: Keystone

Address before: Unit E168 North building two building in Suzhou City, Jiangsu province Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY building A1

Applicant before: Cstone Pharmaceuticals (Suzhou) Co.,Ltd.

Applicant before: Cstone Pharmaceuticals (Shanghai) Co.,Ltd.

Applicant before: Keystone

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant